Preparation process of avian influenza virus split vaccine containing MF59 adjuvant

Abstract

The invention discloses a preparation process of an avian influenza virus split vaccine containing an MF59 adjuvant. The preparation process comprises the following steps of: inoculating an R1203 avian influenza virus strain onto a chicken embryo; inoculating viruses and culturing to obtain a virus liquid; inactivating viruses and purifying; cracking; purifying once again; removing bacteria and filtering, and the like. The preparation process has the beneficial effects that: the vaccine prepared from the MF59 adjuvant has high immunogenicity, and can generate higher antibody response; the immunity of children and the old who cannot generate immune response or have low immune response after inoculation of the conventional vaccine can be enhanced; cross immunity can be generated for different influenza virus subtypes; and on the premise of keeping constant immunity, the antigen content can be lowered, the content of foreign proteins capable of causing side reactions is lowered simultaneously, the side reaction of the vaccine is lower, higher safety is achieved, and the risks of virulence returning strength and variation are avoided.

Description

technical field [0001] The invention belongs to the field of vaccine preparation, in particular to a preparation process of avian influenza virus split vaccine containing MF59 adjuvant. Background technique [0002] Avian influenza is the abbreviation of avian influenza. It is an infectious disease caused by a subtype of influenza A virus (also known as avian influenza virus). True fowl plague or European fowl plague. It is an acute infectious disease caused by avian influenza virus, which can also infect humans. The main symptoms after human infection are high fever, cough, runny nose, myalgia, etc. Most of them are accompanied by severe pneumonia. In severe cases, the heart, kidney, etc. Multiple organ failures lead to death, and the case fatality rate is very high. [0003] Aluminum adjuvants have been used in vaccines for more than 80 years, but recent data have shown that immunosuppression and poisoning occur after the use of aluminum adjuvants in vaccine preparation....

AI Technical Summary

Problems solved by technology

[0003] Aluminum adjuvants have been used in vaccines for more than 80 years, but recent data have shown that immunosuppression and poisoning occur after the use of aluminum adjuvants in vaccine preparation. If the amount used is too small, the adsorption is not complete, and if the amount is too large, the adsorption is complete but there is safety